Genomenon Recognized by Frost & Sullivan for Genomic Intelligence Solutions and Software for Pharma and Clinical Diagnostics Companies

Avatar photo
Business Intelligence

Genomenon’s unique blend of AI technology and expert scientific review delivers deep genomic insights into genetic drivers of rare diseases and cancer.

SAN ANTONIO, May 8, 2023 /PRNewswire/ — Frost & Sullivan today announced that it has awarded Genomenon with the 2023 Global Technology Innovation Leadership Award. Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality that is gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables. Frost & Sullivan market analysts determined that Genomenon excels in many of the criteria and best practices identified as critical for the global pharma and clinical diagnostics genomics markets.

Genomenon is a genomic intelligence software company that combines AI-powered Genomic Language Processing (GLP) with expert review by genetic scientists to deliver the most comprehensive knowledgebase of genomic evidence available. Their fit-for-purpose combinatorial approach to identifying and indexing published genomic evidence gives them a unique advantage over other open access and commercial genomic data resources in this space.

Clinical diagnostic labs rely on Genomenon’s Mastermind Genomic Search Engine to find critical information needed to diagnose rare genetic diseases and identify the most appropriate patient treatment options. Pharmaceutical companies engaged in the development of rare disease therapeutics partner with Genomenon to gain deep insights into the genetic drivers of disease. The Genomenon scientific team leverages information in the Mastermind knowledgebase to provide the genomic intelligence pharmaceutical companies need to better understand disease mechanisms, more accurately estimate disease prevalence, design clinical trials, and prepare documentation for regulatory approvals.

Pavel Zhebrouski, a best practices research analyst at Frost & Sullivan, observed, “Genomenon differentiates itself in the space by providing a unique combination of AI technology and human expertise. Genomenon empowers rare disease pharmaceutical and biotechnology companies to make informed decisions about promising candidates in their pipeline and help propel novel therapeutics to market. Its commitment to innovation and creativity, scientific rigor, and accuracy, while achieving commercial success, differentiates it from competitors,” added Tejashri Khadilkar, Frost & Sullivan industry analyst.

Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:
Claudia Toscano
P: 1.956.533.5915
E: [email protected]

About Genomenon
Genomenon is an AI-driven genomics company focused on making genomic information actionable for patients with rare genetic diseases and cancer. Keeping pace with the ever-evolving body of knowledge within genomics, Genomenon connects current research with patient DNA to accelerate clinical decision-making and pharmaceutical drug discovery and development. For more information, visit genomenon.com

Contact:
Candace Chapman
P: 1.734.794.3075 x708
E: [email protected]

SOURCE Frost & Sullivan

相關文章

澳門行政長官賀一誠祝賀《澳門商業雜誌》成立二十周年

《澳門商業雜誌》和本集團Project Asia Corporation於本周五(5月24日)舉辦酒會,慶祝成立20周年。 澳門行政長官賀一誠致函《澳門商業雜誌》,對雜誌成立二十周年表示祝賀。

首季零售業銷售額按年減少12.5%

澳門統計暨普查局資料顯示,今年第1季零售業銷售額按年減少12.5%至207.1億澳門元,主要是因為去年首季經濟活動復常,消費需求集中釋放而形成高比較基數所致。

政府要求社團辦橫琴旅行團刺激澳門消費

當局敦促澳門社團利用特區政府最新推出的資助和電子消費券計劃,推廣橫琴旅遊,提振澳門城市經濟。

【總監之言】我們

引用Tomasi de Lampedusa的一句名言:為了有所改變,我們必須讓一切保持原狀。 

與新時代一同崛起

二十載風雨兼程,改變的不僅僅是澳門。我們改變了,世界也改變了。二十年前,澳門正沉醉於博彩市場開放初期帶來的興奮,這一決定最終成功將小城打造成世界頂尖的博彩中心,投注量及營運商和政府收入均領先行業。

行政長官:2023年博彩業佔本地生產總值36.2%

行政長官賀一誠週日表示,2023年博彩業佔本地生產總值(GDP)的36.2%,符合政府設定的經濟多元化目標。